<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055024</url>
  </required_header>
  <id_info>
    <org_study_id>NLS-1022</org_study_id>
    <nct_id>NCT05055024</nct_id>
  </id_info>
  <brief_title>An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy</brief_title>
  <official_title>A 6-Month Multicenter, Open-Labelled Extension of the Clinical Trial NLS-1021 in Narcoleptic Patients With and Without Cataplexy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NLS Pharmaceutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NLS Pharmaceutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label extension of the clinical study NLS-1021, evaluating&#xD;
      long-term safety, tolerability, pharmacokinetics (PK), and therapeutic response to treatment&#xD;
      with NLS-2 in adult subjects with narcolepsy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of NLS-2 in adult subjects with narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Summaries of the number and percentage of subjects who experienced Treatment Emergent Adverse Events (TEAEs), TEAEs related to study drug, SAEs, or discontinued study drug or withdrew from the study due to an AE.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Narcolepsy With Cataplexy</condition>
  <condition>Narcolepsy</condition>
  <condition>Narcolepsy Without Cataplexy</condition>
  <arm_group>
    <arm_group_label>NLS-2 (mazindol extended release)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NLS-2 (mazindol extended release) administered once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mazindol</intervention_name>
    <description>Drug: NLS-2</description>
    <arm_group_label>NLS-2 (mazindol extended release)</arm_group_label>
    <other_name>NLS-2</other_name>
    <other_name>mazindol extended release</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject must complete all Study NLS-1021 study requirements and assessments up to&#xD;
             Visit 6;&#xD;
&#xD;
          -  The subject is able, in the opinion of the Investigator, to receive NLS-2 for the&#xD;
             24-week Treatment Phase of this study;&#xD;
&#xD;
          -  Biological females of childbearing potential must agree to use a medically acceptable&#xD;
             double-barrier method of contraception for at least 30 days prior to Day 1 and until&#xD;
             completion of the study;&#xD;
&#xD;
          -  The subject is able to comply with the open-labelled extension design schedule and&#xD;
             other study requirements;&#xD;
&#xD;
          -  The subject provides written informed consent for the open-label extension study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject meets any Exclusion Criteria for Study NLS-1021 at Visit 6 of that study;&#xD;
&#xD;
          -  The subject receives any investigational drug (other than the COVID-19 vaccine) that&#xD;
             is not NLS-2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Camozzi, MD</last_name>
    <role>Study Director</role>
    <affiliation>NLS Pharmaceutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Franco</last_name>
    <phone>512-413-4550</phone>
    <email>jf@nls-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos Camozzi, MD</last_name>
    <phone>+41 79 120 57 40</phone>
    <email>cc@nls-pharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sleep Disorders Center of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>205-599-1020</phone>
      <phone_ext>122</phone_ext>
      <email>wbooth@sleepalabama.com</email>
    </contact>
    <investigator>
      <last_name>Robert Doekel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sleep Medicine Specialists of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-994-1825</phone>
      <email>info@southfloridasleeps.com</email>
    </contact>
    <investigator>
      <last_name>Edward Mezerhane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-851-9934</phone>
      <email>sdale@neurotrials.com</email>
    </contact>
    <investigator>
      <last_name>Russell Rosenberg, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>678-782-5358</phone>
    </contact>
    <investigator>
      <last_name>Phillip Nowlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hawaii Pacific Neuroscience Clinical Research Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>808-564-6141</phone>
      <email>Info@HawaiiNeuroscience.com</email>
    </contact>
    <investigator>
      <last_name>Kore Liow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center For Sleep &amp; Wake Disorders</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>301-654-1575</phone>
      <email>mail@sleepdoc.com</email>
    </contact>
    <investigator>
      <last_name>Helene Emsellem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sleep and Attention Disorders</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>586-254-0707</phone>
    </contact>
    <investigator>
      <last_name>Bart Sangal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Sleep Specialists</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-707-4120</phone>
    </contact>
    <investigator>
      <last_name>Daniel Garber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Respiratory and Sleep Medicine</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-248-0000</phone>
    </contact>
    <investigator>
      <last_name>Thomas Stern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intrepid Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>513-977-8888</phone>
    </contact>
    <investigator>
      <last_name>Bruce Corser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bogan Sleep Consultants</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>803-251-3093</phone>
    </contact>
    <investigator>
      <last_name>Richard Bogan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sleep Therapy &amp; Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>726-444-5230</phone>
      <email>rafati.sue@sleeptrc.com</email>
    </contact>
    <investigator>
      <last_name>James Andry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Cataplexy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mazindol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

